Advances in genomic biomarkers for lethal metastatic castration-resistant prostate cancer
Translational Cancer Research · 2025-06 · 14 (6) · 3281-3285
DOI: 10.21037/tcr-2025-232 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Cancer Research, 2025-06. Verfasst von Sandra A Frimpong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
to last follow-up for alive patients were calculated from the time of study enrollment
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
ORCID-Profile: Benjamin A Teply
Zitieren
APA
Frimpong, S. A., & Teply, B. A. (2025). Advances in genomic biomarkers for lethal metastatic castration-resistant prostate cancer. Translational Cancer Research, 14(6), 3281-3285. https://doi.org/10.21037/tcr-2025-232
Vancouver
Frimpong SA, Teply BA. Advances in genomic biomarkers for lethal metastatic castration-resistant prostate cancer. Translational Cancer Research. 2025;14(6):3281-3285. doi:10.21037/tcr-2025-232
BibTeX
@article{Frimpong2025,
author = {Frimpong, Sandra A and Teply, Benjamin A},
title = {Advances in genomic biomarkers for lethal metastatic castration-resistant prostate cancer},
journal = {Translational Cancer Research},
year = {2025},
volume = {14},
number = {6},
pages = {3281--3285},
doi = {10.21037/tcr-2025-232}
}
EUVIMED